Article
TP53 Alterations Correlate with Response to VEGF/VEGFR Inhibitors: Implications for Targeted Therapeutics.
Molecular cancer therapeutics - 1 Oct 2016
Wheler Jennifer J, Janku Filip, Naing Aung, Li Yali, Stephen Bettzy, Zinner Ralph, Subbiah Vivek, Fu Siqing, Karp Daniel, Falchook Gerald S, Tsimberidou Apostolia M, Piha-Paul Sarina, Anderson Roosevelt, Ke Danxia, Miller Vincent, Yelensky Roman, Lee J Jack, Hong David, Kurzrock Razelle
Abstract excerpt
TP53 tumor-suppressor gene mutations are among the most frequent abnormalities in cancer, affecting approximately 40% of patients. Yet, there is no accepted way to target these alterations in the clinic. At the same time, antagonists of VEGFR or its ligand are best-selling oncology drugs, with multiple, expensive compounds approved. Although only a subset of patients benefit from these antiangiogenesis agents, no...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.